Monitoring treatment response in abdominal sepsis with procalcitonin - if only!

Critical Care

Volumn 17, Issue 6, 2013, Pages

  Eckmann, Christian ^a   Sanchez Garcia, Miguel ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROCALCITONIN; ANTIINFECTIVE AGENT; CALCITONIN; PROTEIN PRECURSOR;

ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; CRITICALLY ILL PATIENT; HEALTH CARE COST; HUMAN; MONITORING; NOTE; PERITONITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REOPERATION; SEPSIS; SEPTIC SHOCK; TREATMENT FAILURE; TREATMENT RESPONSE; BLOOD; FEMALE; INTRAABDOMINAL INFECTIONS; MALE; SHOCK, SEPTIC;

ANTI-INFECTIVE AGENTS; CALCITONIN; FEMALE; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; PROTEIN PRECURSORS; SHOCK, SEPTIC;

EID: 84890094878     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13154     Document Type: Note

References (13)

1. Jung B, Molinari N, Nasri M, Hajjej Z, Chanques G, Jean-Pierre H, Panaro F, Jaber S. Procalcitonin biomarker kinetics fails to predict treatment response in perioperative abdominal infection with septic shock. Crit Care 2013, 17:R255. 10.1186/cc13082, 24156734.
2. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G, Kumar A, Simon D, Peters C, Ahsan M, Chateau D,. Cooperative Antimicrobial Therapy of Septic Shock Database Research Group Initiation of inappropiate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009, 136:1237-1248. 10.1378/chest.09-0087, 19696123, Cooperative Antimicrobial Therapy of Septic Shock Database Research Group.
3. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007, 33:606-618. 10.1007/s00134-006-0517-7, 17323051.
4. Eckmann C, Dryden M, Montravers P, Kozlov R, Sganga G. Antimicrobial treatment of " complicated" intra-abdominal infections and the new IDSA guidelines - a commentary and an alternative European approach. Eur J Med Res 2011, 16:115-126. 10.1186/2047-783X-16-3-115, 3352208, 21486724.
5. Barie P. The cost of failure. Surg Infect 2008, 9:313-331.
6. Lamme B, Mahler CW, van Ruler O, Gouma DJ, Reitsma JB, Boermeester MA. Clinical predictors of ongoing infection in secondary peritonitis: systematic review. World J Surg 2006, 30:2170-2181. 10.1007/s00268-005-0333-1, 17102920.
7. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R,. Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39:165-228. 10.1007/s00134-012-2769-8, 23361625, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup.
8. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596. 10.1097/01.CCM.0000217961.75225.E9, 16625125.
9. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Müller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004, 363:600-607. 10.1016/S0140-6736(04)15591-8, 14987884.
10. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M,. PRORATA trial group Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375:463-474. 10.1016/S0140-6736(09)61879-1, 20097417, PRORATA trial group.
11. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008, 177:498-505. 10.1164/rccm.200708-1238OC, 18096708.
12. Schuetz P, Maurer P, Punjabi V, Desai A, Amin DN, Gluck E. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care 2013, 17:R115. 10.1186/cc12787, 23787145.
13. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Løken J, Steensen M, Fox Z, Tousi H, Søe-Jensen P, Lauritsen A, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjær J, Grarup J, Lundgren JD,. Procalcitonin And Survival Study (PASS) Group Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011, 39:2048-2058. 10.1097/CCM.0b013e31821e8791, 21572328, Procalcitonin And Survival Study (PASS) Group.